Company news
Veracyte, Inc. (NASDAQ:VCYT) news
Every Veracyte, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
October 16, 2024
New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men
October 2, 2024
New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
September 15, 2024
Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors
September 4, 2024
Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
August 26, 2024
Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 26, 2024
Veracyte Announces Second Quarter 2024 Financial Results
August 6, 2024
Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
July 17, 2024
Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
June 3, 2024
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
May 22, 2024
Veracyte Announces First Quarter 2024 Financial Results
May 7, 2024
14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
May 6, 2024
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
April 22, 2024
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
April 22, 2024
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
April 16, 2024
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
February 27, 2024
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
February 22, 2024
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
February 21, 2024
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
February 8, 2024
Veracyte Completes Acquisition of C2i Genomics
February 6, 2024
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
January 8, 2024
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 12, 2023
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
December 1, 2023
Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
November 29, 2023
Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
November 22, 2023
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
November 7, 2023
Veracyte Announces Third Quarter 2023 Financial Results
November 7, 2023
Veracyte to Participate in the Stephens Annual Investment Conference
November 2, 2023
Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development
October 27, 2023
Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023
October 17, 2023
New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease
October 12, 2023
New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier
October 4, 2023
Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023
September 28, 2023
New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
September 28, 2023
Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer
September 27, 2023
Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting
September 21, 2023
Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests
September 7, 2023
Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies
September 6, 2023
Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 29, 2023
Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer
August 22, 2023
Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego
August 15, 2023
Veracyte Announces Second Quarter 2023 Financial Results
August 8, 2023
Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment
August 1, 2023
Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023
July 19, 2023
New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer
June 20, 2023
Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023
June 12, 2023
New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer
May 25, 2023
New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
May 24, 2023
Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
May 12, 2023
New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules
May 4, 2023